This article has been updated with additional information from Memorial Sloan Kettering Cancer Center.

NEW YORK (GenomeWeb) – The US Food and Drug Administration said today that it has authorized Memorial Sloan Kettering Cancer Center's MSK-IMPACT next-generation sequencing tumor profiling assay as an in vitro diagnostic test. In addition, the agency said that it has accredited the New York State Department of Health (NYSDOH) as an FDA third-party reviewer of IVDs, including similar tumor profiling tests.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.